Drug Shortage Report for NOVAMOXIN
Report ID | 169966 |
Drug Identification Number | 00452130 |
Brand name | NOVAMOXIN |
Common or Proper name | TEVA-AMOXICILLIN SUS |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | AMOXICILLIN |
Strength(s) | 250MG |
Dosage form(s) | GRANULES FOR SUSPENSION |
Route of administration | ORAL ORAL |
Packaging size | 100,150 |
ATC code | J01CA |
ATC description | BETA-LACTAM ANTIBACTERIALS, PENICILLINS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2022-09-22 |
Estimated end date | 2023-07-10 |
Actual end date | 2023-07-04 |
Shortage status | Resolved |
Updated date | 2023-07-05 |
Company comments | |
Health Canada comments | |
Tier 3 Status | Yes |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v31 | 2023-07-05 | English | Compare |
v30 | 2023-07-04 | French | Compare |
v29 | 2023-07-04 | English | Compare |
v28 | 2023-06-09 | French | Compare |
v27 | 2023-06-09 | English | Compare |
v26 | 2023-06-09 | English | Compare |
v25 | 2023-06-09 | French | Compare |
v24 | 2023-06-09 | English | Compare |
v23 | 2023-04-27 | French | Compare |
v22 | 2023-04-27 | English | Compare |
v21 | 2023-02-02 | French | Compare |
v20 | 2023-02-02 | English | Compare |
v19 | 2023-01-19 | French | Compare |
v18 | 2023-01-19 | English | Compare |
v17 | 2023-01-12 | French | Compare |
v16 | 2023-01-12 | English | Compare |
v15 | 2022-12-22 | English | Compare |
v14 | 2022-12-01 | French | Compare |
v13 | 2022-12-01 | English | Compare |
v12 | 2022-12-01 | French | Compare |